Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954–963 (2021).

Article  CAS  PubMed  Google Scholar 

Hansson O. et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dement. https://doi.org/10.1002/alz.12756 (2022).

Schindler, S. E. et al. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 93, e1647–e1659 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janelidze, S. et al. Head-to-head comparison of 8 plasma amyloid-beta 42/40 assays in Alzheimer disease. JAMA Neurol. 78, 1375–1382 (2021).

Article  PubMed  Google Scholar 

Ashton, N. J. et al. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology. Acta Neuropathol. 141, 709–724 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772–781 (2020).

Article  CAS  PubMed  Google Scholar 

Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422–433 (2020).

Article  CAS  PubMed  Google Scholar 

Janelidze, S. et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat. Med. 26, 379–386 (2020).

Article  CAS  PubMed  Google Scholar 

Ashton, N. J. et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 12, 3400 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K. & Alzheimer’s Disease Neuroimaging Initiative Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 74, 557–566 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Pereira J. B. et al. Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer’s disease. Brain 144, 3505–3516 (2021).

Benedet, A. L. et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 78, 1471–1483 (2021).

Article  PubMed  Google Scholar 

Palmqvist, S. et al. Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. 27, 1034–1042 (2021).

Article  CAS  PubMed  Google Scholar 

Lantero Rodriguez, J. et al. Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 140, 267–278 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smirnov D. S. et al. Plasma biomarkers for Alzheimer’s disease in relation to neuropathology and cognitive change. Acta Neuropathol. 143, 487–503 (2022).

Salvadó S. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and neurofibrillary tau tangle loads. Preprint at medRxiv https://doi.org/10.1101/2022.08.22.22279052 (2022).

Meyer P. F. et al. Plasma p-tau231, p-tau181, PET biomarkers, and cognitive change in older adults. Ann. Neurol. 91, 548–560 (2022).

Mila-Aloma M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer’s disease. Nat. Med. 28, 1797–1801 (2022).

Mattsson-Carlgren, N. et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease. Brain 143, 3234–3241 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Janelidze, S. et al. Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Abeta42/Abeta40 and p-tau. Alzheimers Dement. 18, 283–293 (2022).

Barthelemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat. Med. 26, 398–407 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klunk, W. E. et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 11, 1–15 e11-14 (2015).

Article  PubMed  Google Scholar 

Wennstrom, M. et al. Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels. Acta Neuropathol. Commun. 10, 3 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H. & Blennow, K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 76, 791–799 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Benedet, A. L. et al. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer’s disease. Brain 143, 3793–3804 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Kaeser, S. A. et al. CSF p-tau increase in response to Abeta-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles. Acta Neuropathol. 143, 287–290 (2022).

Article  CAS  PubMed  Google Scholar 

Mattsson-Carlgren, N. et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol. Med. 13, e14022 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thijssen, E. H. et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 20, 739–752 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karikari T. K. et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat. Rev. Neurol. 18, 400–418 (2022).

Leuzy A. et al. Comparing the clinical utility and diagnostic performance of cerebrospinal fluid p-tau181, p-tau217 and p-tau231 assays. Neurology 97, e1681–e1694 (2021).

Ashton, N. J. et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer’s disease. EBioMedicine 76, 103836 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pontecorvo M. J. et al. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol. Preprint at https://pubmed.ncbi.nlm.nih.gov/36251300/ (2022).

Bayoumy, S. et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res. Ther. 13, 198 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barthelemy, N. R., Horie, K., Sato, C. & Bateman, R. J. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. J. Exp. Med. 217, e20200861 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Schindler S. E. et al. Effect of race on prediction of brain amyloidosis by plasma Abeta42/Abeta40, phosphorylated tau, and neurofilament light. Neurology 99, e245–e257 (2022).

Brickman, A. M. et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer’s disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 17, 1353–1364 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mattsson, N. et al. Increased amyloidogenic APP processing in APOE varepsilon4-negative individuals with cerebral beta-amyloidosis. Nat. Commun. 7, 10918 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151–1162 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Donohue, M. C. et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 71, 961–970 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Papp, K. V., Rentz, D. M., Orlovsky, I., Sperling, R. A. & Mormino, E. C. Optimizing the preclinical Alzheimer’s cognitive composite with semantic processing: the PACC5. Alzheimers Dement. (N. Y.) 3, 668–677 (2017).

Article  PubMed  Google Scholar 

Insel, P. S. et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology 93, e322–e333 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Johnson, S. C. et al. The Wisconsin Registry for Alzheimer’s Prevention: a review of findings and current directions. Alzheimers Dement. (Amst.) 10, 130–142 (2018).

Article  PubMed  Google Scholar 

Jonaitis, E. M. et al. Measuring longitudinal cognition: individual tests versus composites. Alzheimers Dement. (Amst.) 11, 74–84 (2019).

Article  PubMed  Google Scholar 

Jack, C. R. Jr. et al. Defining imaging biomarker cut points for brain aging and Alzheimer’s disease. Alzheimers Dement. 13, 205–216 (2017).

Article  PubMed  Google Scholar 

Bourgeat, P. et al. Implementing the centiloid transformation for (11)C-PiB and beta-amyloid (18)F-PET tracers using CapAIBL. Neuroimage 183, 387–393 (2018).

Article  CAS  PubMed